Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free PAVM Stock Alerts

PAVmed (PAVM) Financials

PAVmed logo
$5.18 0.00 (0.00%)
As of 08/21/2026 03:28 PM Eastern
Compare
Annual Income Statements for PAVmed

Annual Income Statements for PAVmed

This table shows PAVmed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.78 -5.65 -10 -19 -17 -35 -51 -89 -66 32 -3.77
Consolidated Net Income / (Loss)		 -1.78 -5.65 -9.52 -18 -17 -36 -56 -103 -79 28 -2.47
Net Income / (Loss) Continuing Operations		 -1.78 -5.65 -9.52 -18 -17 -36 -56 -103 -79 28 -2.47
Total Pre-Tax Income 		-1.78 -5.65 -9.52 -18 -17 -36 -56 -103 -79 28 -2.47
Total Operating Income		 -1.78 -5.65 -8.03 -11 -14 -23 -54 -91 -69 -44 -22
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 -0.09 -3.24 -3.97 -1.85 -0.15
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.38 2.45 3.00 0.07
Operating Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.38 2.45 3.00 0.07
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.59 3.61 6.42 4.84 0.22
Operating Cost of Revenue		 - - - - - 0.00 0.59 3.61 6.42 4.84 0.22
Total Operating Expenses		 1.78 5.65 8.03 11 14 23 54 88 65 43 22
Selling, General & Admin Expense		 1.29 3.93 5.41 6.31 7.67 9.60 25 41 31 25 16
Marketing Expense		 - - - - - 2.79 8.90 19 18 12 0.92
Research & Development Expense		 0.49 1.72 2.62 4.25 6.63 11 20 25 14 5.93 4.49
Amortization Expense		 - - - - - - 0.15 1.78 2.02 0.56 0.00
Total Other Income / (Expense), net		 0.00 0.00 -1.49 -7.61 -2.97 -13 -1.73 -12 -10 73 19
Interest Expense		 - 0.00 0.72 4.42 1.86 6.55 3.42 6.72 4.37 4.58 0.08
Interest & Investment Income		 - - - - - - - 0.17 0.51 73 0.03
Other Income / (Expense), net		 - 0.00 -0.76 -3.19 -1.11 -5.99 1.68 -5.61 -6.60 4.95 19
Income Tax Expense		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Preferred Stock Dividends Declared		 - 0.00 0.88 0.78 0.27 0.29 0.28 0.28 2.10 7.83 4.18
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - 0.00 -0.20 -0.81 -1.61 -5.78 -14 -15 -11 -2.87
Basic Earnings per Share		 ($0.16) ($0.44) ($0.71) ($0.81) ($0.54) ($1.45) ($0.65) ($15.03) ($9.16) $99.15 ($5.63)
Weighted Average Basic Shares Outstanding		 11.28M 12.97M 13.50M 22.28M 30.20M 47.43M 77.52M 5.94M 7.23M 322.41K 670.47K
Diluted Earnings per Share		 ($0.16) ($0.44) ($0.71) ($0.81) ($0.54) ($1.45) ($0.65) ($15.03) ($9.16) $14.90 ($5.63)
Weighted Average Diluted Shares Outstanding		 11.28M 12.97M 13.50M 22.28M 30.20M 47.43M 77.52M 5.94M 7.23M 2.17M 670.47K
Weighted Average Basic & Diluted Shares Outstanding		 11.28M 12.97M 13.50M 22.28M 30.20M 47.43M 77.52M 98.42M 9.17M 16.79M 6.38M

Quarterly Income Statements for PAVmed

This table shows PAVmed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -16 -23 -11 64 1.35 18 -13 -6.33 -1.83 -6.99 -5.48
Consolidated Net Income / (Loss)		 -17 -19 -15 61 1.14 19 -12 -6.01 -2.76 -1.06 -6.60
Net Income / (Loss) Continuing Operations		 -17 -19 -15 61 1.14 19 -12 -6.01 -2.76 -1.06 -6.60
Total Pre-Tax Income 		-17 -19 -15 61 1.14 19 -12 -6.01 -2.76 -1.06 -6.60
Total Operating Income		 -16 -14 -14 -12 -5.19 -5.45 -4.72 -4.84 -6.80 -8.04 -7.02
Total Gross Profit		 -0.56 -0.73 -0.69 -0.39 -0.04 -0.03 -0.04 -0.05 -0.03 -0.08 -0.09
Total Revenue		 1.05 1.01 0.98 1.00 0.01 0.01 0.01 0.01 0.05 0.02 0.03
Operating Revenue		 1.05 1.01 0.98 1.00 0.01 0.01 0.01 0.01 0.05 0.02 0.03
Total Cost of Revenue		 1.61 1.74 1.67 1.38 0.05 0.04 0.04 0.06 0.09 0.10 0.12
Operating Cost of Revenue		 1.61 1.74 1.67 1.38 0.05 0.04 0.04 0.06 0.09 0.10 0.12
Total Operating Expenses		 16 13 13 11 5.15 5.42 4.68 4.79 6.77 7.96 6.93
Selling, General & Admin Expense		 7.03 6.68 7.01 6.65 4.19 4.38 3.67 3.51 4.69 6.36 4.65
Marketing Expense		 4.69 4.31 4.24 2.92 0.15 0.25 0.22 0.20 0.25 0.22 0.22
Research & Development Expense		 3.60 1.94 1.64 1.54 0.81 0.79 0.79 1.09 1.83 1.39 2.07
Total Other Income / (Expense), net		 -1.03 -4.48 -1.23 72 6.33 24 -7.61 -1.17 4.04 6.97 0.42
Interest Expense		 0.77 2.39 0.77 1.42 0.01 0.06 0.00 0.01 0.01 3.43 0.00
Interest & Investment Income		 0.10 0.07 0.11 72 0.00 0.01 0.01 0.01 0.00 0.02 0.01
Other Income / (Expense), net		 -0.35 -2.16 -0.57 1.35 6.34 24 -7.61 -1.17 4.05 10 0.42
Income Tax Expense		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Preferred Stock Dividends Declared		 1.87 7.58 0.08 0.08 0.09 1.27 1.39 0.95 0.57 6.93 0.10
Net Income / (Loss) Attributable to Noncontrolling Interest		 -3.37 -3.30 -4.09 -3.69 -0.29 -0.35 -0.40 -0.63 -1.49 -1.00 -1.21
Basic Earnings per Share		 ($2.20) ($2.62) ($1.19) $6.43 $4.17 $38.26 ($22.08) ($0.29) ($2.73) ($4.42) ($0.87)
Weighted Average Basic Shares Outstanding		 7.23M 8.69M 9.15M 10.01M 322.41K 462.54K 602.82K 21.55M 670.47K 1.58M 6.27M
Diluted Earnings per Share		 ($2.20) ($2.62) ($1.19) $1.44 $4.17 $10.10 ($22.08) ($0.29) ($2.73) ($4.42) ($0.87)
Weighted Average Diluted Shares Outstanding		 7.23M 8.69M 9.15M 44.48M 2.17M 1.75M 602.82K 21.55M 670.47K 1.58M 6.27M
Weighted Average Basic & Diluted Shares Outstanding		 9.17M 9.43M 10.41M 11.07M 16.79M 17.62M 21.93M 29.67M 6.38M 7.27M 8.00M

Annual Cash Flow Statements for PAVmed

This table details how cash moves in and out of PAVmed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.07 -0.18 0.95 6.69 -2.00 11 60 -38 -20 -18 0.35
Net Cash From Operating Activities		 -1.25 -4.45 -6.61 -8.79 -13 -22 -41 -71 -52 -34 -5.21
Net Cash From Continuing Operating Activities		 -1.25 -4.45 -6.61 -8.79 -13 -22 -41 -71 -52 -34 -5.21
Net Income / (Loss) Continuing Operations		 -1.78 -5.65 -9.52 -18 -17 -36 -56 -103 -79 28 -2.47
Consolidated Net Income / (Loss)		 -1.78 -5.65 -9.52 -18 -17 -36 -56 -103 -79 28 -2.47
Depreciation Expense		 0.00 0.00 0.01 0.01 0.01 0.02 0.23 2.46 2.93 1.20 0.11
Non-Cash Adjustments To Reconcile Net Income		 0.13 0.75 2.64 6.49 3.32 14 17 31 23 -64 -2.94
Changes in Operating Assets and Liabilities, net		 0.39 0.44 -0.08 1.28 0.58 0.08 -1.57 -0.72 1.59 0.51 0.10
Net Cash From Investing Activities		 0.00 -0.02 -0.01 -0.03 -0.03 -0.06 -3.72 -4.74 0.76 -16 -0.03
Net Cash From Continuing Investing Activities		 0.00 -0.02 -0.01 -0.03 -0.03 -0.06 -3.72 -4.74 0.76 -16 -0.03
Purchase of Property, Plant & Equipment		 0.00 -0.02 -0.01 -0.03 -0.03 -0.06 -1.47 -1.54 -0.24 -0.06 -0.03
Acquisitions		 - - - - - 0.00 -2.25 -3.20 - -16 0.00
Divestitures		 - - - - - - - - - 0.35 0.00
Net Cash From Financing Activities		 1.18 4.30 7.56 16 11 33 104 38 31 31 5.59
Net Cash From Continuing Financing Activities		 1.18 4.30 7.56 16 11 33 104 38 31 31 5.59
Repayment of Debt		 - - 0.00 -5.00 -0.37 -0.60 -15 0.00 -0.08 -0.53 0.00
Repurchase of Common Equity		 -0.07 0.00 -0.39 0.00 - - -1.31 - - 0.00 -0.11
Issuance of Preferred Equity		 - 0.00 3.04 - - - - 0.00 19 30 0.00
Issuance of Common Equity		 0.00 5.30 0.07 14 5.48 16 117 0.44 1.79 1.66 5.70
Other Financing Activities, net		 1.25 - 0.00 -0.34 -0.03 -0.09 8.80 2.55 0.84 0.00 0.00

Quarterly Cash Flow Statements for PAVmed

This table details how cash moves in and out of PAVmed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -6.77 5.90 -0.04 -25 0.42 1.52 1.30 -0.90 -1.57 4.92 -2.68
Net Cash From Operating Activities		 -12 -13 -12 -8.88 0.09 -1.58 -1.18 -0.90 -1.55 -2.62 -2.66
Net Cash From Continuing Operating Activities		 -12 -13 -12 -8.88 0.09 -1.58 -1.18 -0.90 -1.55 -2.62 -2.66
Net Income / (Loss) Continuing Operations		 -17 -19 -15 61 1.14 19 -12 -6.01 -2.76 -1.06 -6.60
Consolidated Net Income / (Loss)		 -17 -19 -15 61 1.14 19 -12 -6.01 -2.76 -1.06 -6.60
Depreciation Expense		 0.73 0.59 0.31 0.24 0.07 0.04 0.02 0.02 0.02 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income		 2.69 4.44 3.38 -69 -2.19 -20 11 4.91 1.01 -1.52 3.98
Changes in Operating Assets and Liabilities, net		 2.12 0.38 -0.42 -0.52 1.08 -0.33 0.07 0.18 0.18 -0.06 -0.06
Net Cash From Investing Activities		 -0.18 -0.04 -0.00 -16 -0.00 -0.01 -0.01 -0.00 -0.01 -0.02 -0.01
Net Cash From Continuing Investing Activities		 -0.18 -0.04 -0.00 -16 -0.00 -0.01 -0.01 -0.00 -0.01 -0.02 -0.01
Purchase of Property, Plant & Equipment		 -0.18 -0.04 -0.00 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.02 -0.01

Annual Balance Sheets for PAVmed

This table presents PAVmed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.21 0.87 1.64 8.50 7.24 20 87 54 33 31 39
Total Current Assets		 0.78 0.74 1.62 8.46 6.55 19 83 44 24 2.16 2.56
Cash & Equivalents		 0.77 0.59 1.54 8.22 6.22 17 77 40 20 1.19 1.54
Accounts Receivable		 - - - - - 0.00 0.20 0.02 0.06 0.02 0.02
Prepaid Expenses		 0.01 0.16 0.09 0.24 0.33 1.69 5.18 4.05 4.52 0.96 1.00
Plant, Property, & Equipment, net		 0.00 0.02 0.02 0.00 0.00 0.08 1.59 2.45 1.78 0.15 0.08
Total Noncurrent Assets		 0.44 0.11 0.00 0.04 0.69 0.76 2.75 7.60 6.84 28 36
Long-Term Investments		 - - - - - - - - 0.00 26 34
Other Noncurrent Operating Assets		 0.44 0.11 - 0.04 0.69 0.76 0.73 4.16 5.41 2.71 2.06
Total Liabilities & Shareholders' Equity		 1.21 0.87 1.64 8.50 7.24 20 87 54 33 31 39
Total Liabilities		 0.58 1.19 4.49 11 12 20 7.56 43 57 38 17
Total Current Liabilities		 0.58 1.19 2.54 11 12 16 7.56 41 54 35 15
Short-Term Debt		 - - 0.00 7.90 8.14 10 0.00 34 44 29 11
Accounts Payable		 0.17 0.95 0.86 1.74 2.35 2.97 3.30 2.70 1.79 0.66 0.68
Accrued Expenses		 0.41 0.24 0.71 1.33 1.39 2.33 4.26 3.71 6.63 5.18 2.49
Other Current Liabilities		 - 0.00 0.97 - - - 0.00 1.14 1.57 0.51 0.57
Total Noncurrent Liabilities		 0.00 0.00 1.94 0.00 0.00 4.60 0.00 1.85 2.96 2.25 1.68
Long-Term Debt		 - 0.00 1.94 - - - - - - - 0.00
Other Noncurrent Operating Liabilities		 - - - - 0.00 4.60 0.00 1.85 2.96 2.25 1.68
Commitments & Contingencies		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.63 -0.32 -2.85 -2.48 -4.64 -0.47 79 11 -24 -7.03 22
Total Preferred & Common Equity		 0.63 -0.32 -2.85 -2.31 -3.82 1.90 62 -9.68 -54 -2.50 34
Preferred Stock		 0.00 - 1.03 - 2.30 2.54 2.42 2.70 2.99 3.32 25
Total Common Equity		 0.63 -0.32 -3.88 -2.31 -6.12 -0.64 59 -12 -57 -5.81 9.29
Common Stock		 2.68 7.38 14 33 48 88 198 216 238 249 268
Retained Earnings		 -2.05 -7.70 -18 -37 -54 -88 -139 -228 -294 -255 -259
Noncontrolling Interest		 - - 0.00 -0.16 -0.81 -2.37 18 21 30 -4.54 -12

Quarterly Balance Sheets for PAVmed

This table presents PAVmed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 42 37 39 31 53 44 38 45 40
Total Current Assets		 32 30 30 2.13 3.64 5.49 4.19 7.41 4.86
Cash & Equivalents		 26 26 25 0.77 2.70 4.00 3.10 6.46 3.78
Accounts Receivable		 0.04 0.07 0.22 0.02 0.01 0.00 0.00 0.02 0.02
Prepaid Expenses		 6.02 3.56 3.80 1.34 0.93 1.48 1.09 0.93 1.06
Plant, Property, & Equipment, net		 1.82 1.60 1.33 0.22 0.11 0.10 0.08 0.08 0.07
Total Noncurrent Assets		 7.74 6.09 7.88 28 49 38 34 38 35
Long-Term Investments		 - - - 26 47 36 32 36 33
Other Noncurrent Operating Assets		 5.81 5.03 6.93 2.69 2.43 2.31 2.18 1.93 1.79
Total Liabilities & Shareholders' Equity		 42 37 39 31 53 44 38 45 40
Total Liabilities		 58 58 58 40 12 12 12 20 21
Total Current Liabilities		 55 55 53 38 9.78 11 10 3.66 4.09
Short-Term Debt		 45 46 44 32 6.60 6.80 6.90 0.00 0.00
Accounts Payable		 2.17 1.49 1.23 0.47 0.37 0.39 0.34 0.98 1.06
Accrued Expenses		 5.49 6.66 6.79 4.54 2.28 2.78 2.66 2.09 2.46
Other Current Liabilities		 1.87 1.33 1.37 0.50 0.53 0.54 0.56 0.59 0.57
Total Noncurrent Liabilities		 3.34 2.81 4.67 2.38 2.11 1.97 1.82 17 17
Long-Term Debt		 - - - - - - - 15 15
Other Noncurrent Operating Liabilities		 3.34 2.81 4.67 2.38 2.11 1.97 1.82 1.87 1.72
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -16 -21 -19 -9.39 39 28 23 25 19
Total Preferred & Common Equity		 -43 -69 -74 -4.87 45 38 33 40 35
Preferred Stock		 2.92 3.07 3.15 3.23 26 25 24 3.76 3.85
Total Common Equity		 -46 -72 -77 -8.10 19 13 8.45 36 31
Common Stock		 232 238 244 248 256 264 265 295 296
Retained Earnings		 -279 -310 -321 -256 -237 -251 -257 -259 -265
Noncontrolling Interest		 27 48 55 -4.52 -6.06 -9.37 -9.99 -15 -16

Annual Metrics And Ratios for PAVmed

This table displays calculated financial ratios and metrics derived from PAVmed's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 13,310,000.00 13,875,061.00 26,542,979.00 36,759,128.00 52,254,847.00 87,930,411.00 93,704,719.00 120,759,886.00 11,068,566.00 29,671,925.00
DEI Adjusted Shares Outstanding		 0.00 34,240.00 35,694.00 68,283.00 94,564.00 134,427.00 226,204.00 241,059.00 310,659.00 368,952.00 989,064.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -165.04 -291.31 -274.60 -176.89 -257.11 -223.82 -370.30 -213.32 86.64 -3.82
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -24.60% 550.40% 22.15% -97.63%
EBITDA Growth		 0.00% 0.00% -49.46% -43.85% -26.76% -90.48% -79.04% -79.55% 23.10% 47.10% 93.96%
EBIT Growth		 0.00% 0.00% -55.63% -56.43% -11.97% -90.46% -79.67% -83.44% 22.02% 47.57% 93.88%
NOPAT Growth		 0.00% 0.00% -42.18% -31.48% -35.33% -63.35% -132.94% -67.46% 24.47% 7.62% 65.69%
Net Income Growth		 0.00% 0.00% -68.46% -90.91% 4.98% -107.83% -56.39% -83.94% 23.22% 135.86% -108.69%
EPS Growth		 0.00% 0.00% -61.36% -14.08% 33.33% -168.52% 55.17% -83.94% 39.06% 135.86% -108.69%
Operating Cash Flow Growth		 0.00% -256.50% -48.34% -32.98% -51.99% -64.06% -85.23% -74.88% 26.69% 35.52% 84.48%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% -72.10% -43.27% -15.98% -307.06% -39.57% 33.99% 10.65% 54.68%
Invested Capital Growth		 0.00% 0.00% -169.59% -14.60% 2.76% -171.12% 129.31% 124.07% -88.78% -975.69% 52.51%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 150.00% -33.27% 61.85% -25.76% 144.83%
EBITDA Q/Q Growth		 0.00% 0.00% -9.97% -102.83% -15.13% 19.01% -68.05% -3.97% 9.26% 31.00% -241.27%
EBIT Q/Q Growth		 0.00% 0.00% -11.94% -88.87% -15.12% 18.94% -68.77% -4.49% 8.94% 31.14% -263.23%
NOPAT Q/Q Growth		 0.00% 0.00% -2.26% -15.57% -9.80% -16.77% -27.52% -5.71% 10.67% 20.10% 24.41%
Net Income Q/Q Growth		 0.00% 0.00% 21.33% -37.61% -16.59% 32.44% -117.80% -4.98% 8.29% 187.78% -272.66%
EPS Q/Q Growth		 0.00% 0.00% 22.83% -17.39% -31.71% -35.51% -27.45% -4.98% 3.58% 187.78% -272.66%
Operating Cash Flow Q/Q Growth		 0.00% -14.23% -6.17% -19.47% -8.71% -13.69% -32.90% -0.06% 8.68% 26.29% -46.19%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 38.44% -8.42% 13.35% -58.74% 5.07% 11.20% 20.53% 18.44%
Invested Capital Q/Q Growth		 0.00% 0.00% 66.38% -25.92% -33.72% -190.81% 189.85% -33.43% -80.28% -31.61% -11.18%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17.00% -858.62% -161.83% -61.60% -207.04%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,497.00% -24,996.02% -2,955.34% -1,280.00% -3,259.15%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,878.60% -24,161.01% -2,805.67% -1,485.38% -30,712.68%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,542.20% -25,647.75% -3,074.92% -1,320.00% -3,407.04%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11,225.20% -27,384.08% -3,232.59% 949.15% -3,477.46%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 108.24% 132.10% 112.10% 122.33% 106.48% 106.77% 105.13% -71.91% 102.07%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,821.74% -1,789.21% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,727.02% -2,126.09% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,593.22% 3,000.81% 0.00% 0.00%
Return on Equity (ROE)		 -280.26% -3,589.54% 601.07% 682.61% 485.45% 1,404.34% -142.19% -228.52% 1,211.60% -183.10% -32.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,203.89% -1,898.31% -1,629.56% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -98.75% -137.19% -173.13% -123.97% -6.96%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -105.15% -146.48% -182.01% 89.14% -7.11%
Return on Common Equity (ROCE)		 -280.26% -3,589.54% 797.04% 794.29% 575.56% 1,857.71% -105.56% -118.55% 6,408.04% -369.34% -7.37%
Return on Equity Simple (ROE_SIMPLE)		 -280.26% 1,771.05% 334.20% 785.12% 451.57% -1,892.83% -91.02% 1,066.40% 147.24% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.24 -3.96 -5.62 -7.39 -10 -16 -38 -64 -48 -44 -15
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,615.02% -16,912.71% -1,963.97% -1,485.38% -21,498.87%
Net Nonoperating Expense Percent (NNEP)		 -69.46% -289.45% -4,415.69% 23,918.64% 907.19% -785.46% -42.90% -94.72% 336.89% -543.34% 114.86%
Return On Investment Capital (ROIC_SIMPLE)		 -196.18% - - - - - - - -238.61% -201.60% -45.70%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 117.00% 958.62% 261.83% 161.60% 307.04%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5,084.00% 10,984.08% 1,262.11% 818.83% 22,887.32%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,969.40% 6,720.95% 582.22% 198.06% 6,326.76%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10,861.60% 23,302.39% 2,643.84% 1,423.77% 30,505.63%
Earnings before Interest and Taxes (EBIT)		 -1.78 -5.65 -8.79 -14 -15 -29 -53 -97 -75 -40 -2.42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.78 -5.65 -8.44 -12 -15 -29 -52 -94 -72 -38 -2.31
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 4.23 0.00 0.00 0.00 0.71
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 4.38 0.00 0.00 0.00 0.71
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 500.82 138.11 15.66 2.32 92.28
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.22 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 460.24% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 89.50 14.32 176.36 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 386.64 183.78 39.06 2.67 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 -0.68 -3.19 -1.75 -21.90 0.00 3.08 -1.84 -4.14 0.50
Long-Term Debt to Equity		 0.00 0.00 -0.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.21 1.84 0.06 -0.02 -0.23 0.97 -1.07 -0.92 -1.41 -0.86 -1.46
Leverage Ratio		 1.92 6.62 -0.79 -1.90 -2.21 -5.29 1.35 1.56 -6.66 -2.05 4.55
Compound Leverage Factor		 1.92 6.62 -0.86 -2.51 -2.48 -6.47 1.44 1.67 -7.00 1.48 4.64
Debt to Total Capital		 0.00% 0.00% -215.05% 145.63% 232.48% 104.78% 0.00% 75.48% 219.01% 131.87% 33.23%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 145.63% 232.48% 104.78% 0.00% 75.48% 219.01% 131.87% 33.23%
Long-Term Debt to Total Capital		 0.00% 0.00% -215.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% -114.22% 0.00% 65.58% 25.66% 3.05% 6.04% 14.83% 15.03% 73.89%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% -2.98% -23.25% -23.96% 22.35% 46.24% 147.72% -20.56% -34.93%
Common Equity to Total Capital		 100.00% 100.00% 429.27% -42.65% -174.81% -6.48% 74.60% -27.76% -281.56% -26.33% 27.81%
Debt to EBITDA		 0.00 0.00 -0.23 -0.65 -0.53 -0.35 0.00 -0.36 -0.61 -0.76 -4.80
Net Debt to EBITDA		 0.00 0.00 -0.05 0.03 -0.12 0.24 0.00 0.06 -0.34 -0.06 10.61
Long-Term Debt to EBITDA		 0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.35 -1.07 -0.81 -0.63 0.00 -0.53 -0.92 -0.65 -0.73
Net Debt to NOPAT		 0.00 0.00 -0.07 0.04 -0.19 0.42 0.00 0.10 -0.51 -0.05 1.61
Long-Term Debt to NOPAT		 0.00 0.00 -0.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 19.20 -28.76 -10.18 -15.71 -7.14 16.68 -11.04 -20.56 -16.99 -9.68
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% -32.60% -16.36% -18.56% -32.28% 25.76% 48.12% -428.89% -101.72% 77.22%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.34 0.62 0.64 0.77 0.55 1.21 10.93 1.07 0.45 0.06 0.17
Quick Ratio		 1.32 0.49 0.60 0.75 0.52 1.10 10.25 0.97 0.36 0.03 0.10
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 -4.09 -7.04 -10 -12 -48 -66 -44 -39 -18
Operating Cash Flow to CapEx		 0.00% -20,441.69% -124,659.65% -33,026.07% -49,470.37% -39,843.64% -2,763.17% -4,609.42% 0.00% -61,007.27% -16,793.55%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -5.64 -1.59 -5.41 -1.79 -13.94 -9.89 -10.03 -8.56 -224.83
Operating Cash Flow to Interest Expense		 0.00 0.00 -9.12 -1.99 -7.17 -3.35 -11.89 -10.57 -11.90 -7.33 -65.90
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -9.13 -2.00 -7.18 -3.35 -12.32 -10.80 -11.73 -7.34 -66.29
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.06 0.09 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.47 62.87 75.82 4.30
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 33.01 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.60 0.19 1.16 3.10 0.62
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.19 1.20 2.86 3.96 0.33
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 105.05 5.81 4.81 84.82
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.06 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 1,954.47 303.14 127.64 92.12 1,117.60
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 -1,954.47 -198.09 -110.77 -87.30 -1,032.78
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.13 -0.90 -2.44 -2.80 -2.72 -7.37 2.16 4.84 0.54 -4.76 -2.26
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 -0.19 0.11 0.91 -1.42 -0.02
Increase / (Decrease) in Invested Capital		 0.00 0.00 -1.53 -0.36 0.08 -4.65 9.53 2.68 -4.30 -5.30 2.50
Enterprise Value (EV)		 0.00 106 38 29 54 122 193 69 96 8.00 -5.00
Market Capitalization		 0.00 106 37 30 51 128 250 52 38 6.95 6.55
Book Value per Share		 $0.06 ($0.02) ($0.28) ($0.09) ($0.17) ($0.01) $0.67 ($0.13) ($0.47) ($0.53) $0.31
Tangible Book Value per Share		 $0.06 ($0.02) ($0.28) ($0.09) ($0.17) ($0.01) $0.65 ($0.17) ($0.48) ($0.53) $0.31
Total Capital		 0.63 -0.32 -0.90 5.43 3.50 9.89 79 45 20 22 33
Total Debt		 0.00 0.00 1.94 7.90 8.14 10 0.00 34 44 29 11
Total Long-Term Debt		 0.00 0.00 1.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.77 -0.59 0.41 -0.32 1.92 -6.90 -77 -6.09 25 2.28 -25
Capital Expenditures (CapEx)		 0.00 0.02 0.01 0.03 0.03 0.06 1.47 1.54 -0.76 0.06 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.57 -1.03 -2.46 -2.83 -3.41 -3.61 -2.18 -3.37 -5.12 -5.37 -2.72
Debt-free Net Working Capital (DFNWC)		 0.20 -0.45 -0.92 5.39 2.81 14 75 36 15 -4.18 -1.18
Net Working Capital (NWC)		 0.20 -0.45 -0.92 -2.51 -5.33 3.29 75 2.73 -30 -33 -12
Net Nonoperating Expense (NNE)		 0.53 1.70 3.90 11 7.26 20 18 39 31 -73 -13
Net Nonoperating Obligations (NNO)		 -0.77 -0.59 0.41 -0.32 1.92 -6.90 -77 -6.09 25 2.28 -25
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.35 1.62 0.01 0.02 0.23 2.46 2.93 1.20 0.11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -435.80% -893.37% -208.73% -179.20% -3,828.17%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15,015.80% 9,648.81% 592.21% -139.63% -1,661.97%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15,015.80% 723.08% -1,210.40% -1,111.25% -17,295.77%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($5.70) ($9.20) ($10.50) ($7.00) ($9.33) ($16.84) ($12.96) ($9.16) $99.00 ($5.63)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.00M 1.33M 2.15M 2.33M 6.36M 6.77M 6.87M 7.23M 322.41K 670.47K
Adjusted Diluted Earnings per Share		 $0.00 ($5.70) ($9.20) ($10.50) ($7.00) ($9.33) ($16.84) ($12.96) ($9.16) $15.00 ($5.63)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.00M 1.33M 2.15M 2.33M 6.36M 6.77M 7.60M 7.23M 2.18M 670.47K
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($5.70) ($9.20) ($10.50) ($7.00) ($9.33) ($16.84) ($12.96) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.00M 1.04M 1.72M 2.33M 3.66M 5.98M 7.60M 9.17M 559.57K 6.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.24 -3.96 -5.62 -7.39 -10 -16 -38 -64 -48 -31 -15
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,615.02% -16,912.71% -1,963.97% -1,039.76% -21,498.87%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11,225.20% -27,384.08% -3,232.59% 949.15% -3,477.46%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -12.14 -3.12 -8.26 -4.48 -15.44 -14.40 -17.25 -8.63 -30.62
NOPAT to Interest Expense		 0.00 0.00 -7.76 -1.67 -5.37 -2.50 -11.15 -9.50 -11.02 -9.71 -193.22
EBIT Less CapEx to Interest Expense		 0.00 0.00 -12.14 -3.12 -8.28 -4.49 -15.87 -14.63 -17.08 -8.64 -31.01
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -7.77 -1.68 -5.38 -2.50 -11.58 -9.72 -10.84 -9.73 -193.61
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -4.06% 0.00% -4.08% 0.00% 0.00% 0.00% -2.34% 0.00% 0.00% 0.00% -4.41%

Quarterly Metrics And Ratios for PAVmed

This table displays calculated financial ratios and metrics derived from PAVmed's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 120,759,886.00 9,172,331.00 9,431,721.00 10,406,433.00 11,068,566.00 16,787,173.00 17,618,034.00 21,932,914.00 29,671,925.00 6,383,089.00 7,272,739.00
DEI Adjusted Shares Outstanding		 310,659.00 305,744.00 314,391.00 346,881.00 368,952.00 559,572.00 587,268.00 731,097.00 989,064.00 6,383,089.00 7,272,739.00
DEI Earnings Per Adjusted Shares Outstanding		 -51.20 -74.53 -34.70 185.41 3.65 31.62 -22.66 -8.66 -1.85 -1.09 -0.75
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 836.61% 126.46% 489.76% 25.92% -99.05% -99.21% -99.39% -99.50% 420.00% 175.00% 450.00%
EBITDA Growth		 31.60% 25.30% 14.64% 48.00% 107.59% 219.90% 11.75% 40.05% -325.27% -87.38% 46.47%
EBIT Growth		 30.66% 25.10% 16.59% 48.72% 106.85% 215.30% 13.49% 41.23% -340.40% -87.46% 46.41%
NOPAT Growth		 33.41% 31.20% 16.99% -6.52% 54.75% 44.57% 65.54% 70.71% 8.25% -3.28% -48.93%
Net Income Growth		 29.16% 16.67% 16.64% 379.13% 106.56% 200.60% 17.37% -109.90% -341.42% -105.71% 46.46%
EPS Growth		 36.42% 5.76% 43.33% 160.50% 106.56% 200.60% 17.37% -120.14% -341.42% -143.76% 96.06%
Operating Cash Flow Growth		 29.42% 19.88% 8.30% 19.89% 100.79% 87.94% 89.89% 89.91% -1,750.00% -65.72% -126.06%
Free Cash Flow Firm Growth		 63.97% 82.94% 58.82% 17.97% 101.52% -22.68% 62.65% 4.57% -6,758.44% -15.58% -130.77%
Invested Capital Growth		 -88.78% -109.80% -102.82% -231.19% -975.69% -216.81% -1,164.54% 43.79% 52.51% -42.07% -61.02%
Revenue Q/Q Growth		 32.62% -3.72% -3.07% 1.74% -99.00% -20.00% -25.00% -16.67% 940.00% -57.69% 50.00%
EBITDA Q/Q Growth		 16.69% 2.48% 10.68% 28.34% 112.16% 1,440.74% -165.74% 51.32% 54.31% 186.30% -378.87%
EBIT Q/Q Growth		 16.12% 3.20% 12.03% 28.20% 111.20% 1,529.76% -166.01% 51.22% 54.18% 185.01% -382.07%
NOPAT Q/Q Growth		 -5.50% 14.32% 2.51% -20.87% 55.18% -4.95% 39.40% -2.74% -40.40% -18.14% 12.61%
Net Income Q/Q Growth		 19.97% -6.35% 19.44% 507.07% -98.12% 1,530.74% -166.18% 51.23% 54.13% 61.41% -520.11%
EPS Q/Q Growth		 7.56% -19.09% 54.58% 221.01% -98.12% 1,530.74% -166.18% 60.81% 54.13% -61.90% 80.32%
Operating Cash Flow Q/Q Growth		 -7.08% -10.40% 11.08% 23.79% 101.06% -1,781.91% 25.49% 23.94% -73.10% -68.92% -1.64%
Free Cash Flow Firm Q/Q Growth		 -12.87% 52.16% -29.46% -17.34% 102.09% -3,960.55% 60.59% -199.84% -45.95% 32.99% 21.30%
Invested Capital Q/Q Growth		 -80.28% -205.16% 75.31% -2,462.41% -31.61% 61.96% 1.44% -13.91% -11.18% -13.82% -11.71%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -53.48% -72.67% -70.17% -38.65% -390.00% -350.00% -583.33% -1,000.00% -65.38% -340.91% -269.70%
EBITDA Margin		 -1,526.22% -1,545.84% -1,424.41% -1,003.31% 12,150.00% 234,000.00% -205,100.00% -119,820.00% -5,263.46% 10,736.36% -19,960.61%
Operating Margin		 -1,561.68% -1,389.70% -1,397.75% -1,162.45% -51,890.00% -68,075.00% -78,583.33% -96,880.00% -13,078.85% -36,522.73% -21,278.79%
EBIT Margin		 -1,595.33% -1,603.86% -1,455.57% -1,027.21% 11,460.00% 233,462.50% -205,466.67% -120,260.00% -5,298.08% 10,645.45% -20,018.18%
Profit (Net Income) Margin		 -1,659.39% -1,832.87% -1,523.39% 6,095.48% 11,420.00% 232,787.50% -205,400.00% -120,220.00% -5,301.92% -4,836.36% -19,993.94%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 104.02% 114.28% 104.66% -593.40% 99.65% 99.71% 99.97% 99.97% 100.07% -45.43% 99.88%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -995.90% -1,117.05% -1,543.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,060.23% -1,232.69% -1,586.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 1,496.42% 1,895.40% 1,982.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 500.52% 778.35% 439.60% -78.35% -183.10% 644.12% 1,066.79% 17.44% -32.34% -67.22% -64.78%
Cash Return on Invested Capital (CROIC)		 -1,629.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -89.82% -94.35% -119.73% -114.20% 1,076.30% 10,330.96% -5,031.47% -101.65% -10.83% 18.42% -53.31%
Return on Assets (ROA)		 -93.43% -107.82% -125.31% 677.67% 1,072.54% 10,301.09% -5,029.84% -101.62% -10.84% -8.37% -53.25%
Return on Common Equity (ROCE)		 2,647.22% 7,701.04% 2,516.06% -168.65% -369.34% -1,681.26% -5,354.92% 0.37% -7.37% -55.56% -56.39%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 109.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -9.83 -9.58 -12 -5.19 -5.45 -3.30 -3.39 -4.76 -5.62 -4.92
NOPAT Margin		 -1,093.17% -972.79% -978.43% -1,162.45% -51,890.00% -68,075.00% -55,008.33% -67,816.00% -9,155.19% -25,565.91% -14,895.15%
Net Nonoperating Expense Percent (NNEP)		 64.33% 115.64% 43.86% -593.60% -47.18% 211.72% -122.76% -23.77% 17.99% 12.97% -6.08%
Return On Investment Capital (ROIC_SIMPLE)		 -56.82% -39.36% -37.77% -51.09% -23.51% -11.96% -9.44% -11.52% -14.25% -14.10% -14.29%
Cost of Revenue to Revenue		 153.48% 172.67% 170.17% 138.65% 490.00% 450.00% 683.33% 1,100.00% 165.38% 440.91% 369.70%
SG&A Expenses to Revenue		 670.16% 661.19% 715.93% 667.57% 41,880.00% 54,800.00% 61,166.67% 70,100.00% 9,021.15% 28,890.91% 14,093.94%
R&D to Revenue		 342.80% 192.18% 167.62% 154.82% 8,080.00% 9,837.50% 13,166.67% 21,760.00% 3,513.46% 6,309.09% 6,263.64%
Operating Expenses to Revenue		 1,508.20% 1,317.03% 1,327.58% 1,123.80% 51,500.00% 67,725.00% 78,000.00% 95,880.00% 13,013.46% 36,181.82% 21,009.09%
Earnings before Interest and Taxes (EBIT)		 -17 -16 -14 -10 1.15 19 -12 -6.01 -2.76 2.34 -6.61
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -16 -14 -9.99 1.22 19 -12 -5.99 -2.74 2.36 -6.59
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.65 0.82 1.12 0.71 1.81 1.38
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.65 0.82 1.12 0.71 1.81 1.38
Price to Revenue (P/Rev)		 15.66 6.51 2.01 3.17 2.32 6.08 10.37 325.97 92.28 762.22 385.71
Price to Earnings (P/E)		 0.00 0.00 0.00 0.87 0.22 0.17 0.15 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 114.96% 460.24% 598.24% 662.33% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 176.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 39.06 30.14 22.11 4.29 2.67 0.00 0.00 0.00 0.00 311.20 81.53
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -1.84 -2.21 -2.36 -3.41 -4.14 0.16 0.22 0.27 0.50 0.60 0.78
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.60 0.78
Financial Leverage		 -1.41 -1.54 -1.25 -0.97 -0.86 -1.12 -1.15 -1.34 -1.46 -1.07 -1.09
Leverage Ratio		 -6.66 -10.49 -4.78 -2.88 -2.05 4.42 6.52 4.18 4.55 1.49 1.66
Compound Leverage Factor		 -6.92 -11.99 -5.00 17.08 -2.05 4.41 6.52 4.18 4.55 -0.68 1.66
Debt to Total Capital		 219.01% 182.42% 173.52% 141.42% 131.87% 13.89% 17.79% 21.11% 33.23% 37.35% 43.89%
Short-Term Debt to Total Capital		 219.01% 182.42% 173.52% 141.42% 131.87% 13.89% 17.79% 21.11% 33.23% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 37.35% 43.89%
Preferred Equity to Total Capital		 14.83% 12.30% 12.43% 14.26% 15.03% 55.28% 64.29% 73.63% 73.89% 9.42% 11.19%
Noncontrolling Interests to Total Capital		 147.72% 193.09% 218.09% -19.94% -20.56% -8.55% -15.99% -20.60% -34.93% -36.44% -45.75%
Common Equity to Total Capital		 -281.56% -287.81% -304.03% -35.75% -26.33% 39.38% 33.91% 25.86% 27.81% 89.67% 90.67%
Debt to EBITDA		 -0.61 -0.68 -0.68 -0.58 -0.76 -1.65 -2.88 4.21 -4.80 -0.80 -1.17
Net Debt to EBITDA		 -0.34 -0.30 -0.29 -0.10 -0.06 10.68 14.04 -16.98 10.61 1.48 1.71
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.80 -1.17
Debt to NOPAT		 -0.92 -1.04 -1.05 -0.58 -0.65 -0.18 -0.25 -0.34 -0.73 -0.87 -0.81
Net Debt to NOPAT		 -0.51 -0.46 -0.44 -0.10 -0.05 1.19 1.23 1.38 1.61 1.61 1.19
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.87 -0.81
Altman Z-Score		 -14.71 -13.61 -13.11 -13.92 -12.61 -4.61 -8.52 -9.70 -9.71 -5.81 -8.49
Noncontrolling Interest Sharing Ratio		 -428.89% -889.41% -472.36% -115.25% -101.72% 361.02% 601.96% 97.85% 77.22% 17.35% 12.95%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.45 0.54 0.57 0.06 0.06 0.37 0.52 0.40 0.17 2.02 1.19
Quick Ratio		 0.36 0.47 0.48 0.02 0.03 0.28 0.38 0.30 0.10 1.77 0.93
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.17 -3.43 -4.44 -5.21 0.11 -4.21 -1.66 -4.97 -7.26 -4.86 -3.83
Operating Cash Flow to CapEx		 -6,488.52% -31,211.90% -388,533.33% -148,050.00% 2,350.00% -26,350.00% -14,725.00% -29,866.67% -11,078.57% -11,909.09% -20,484.62%
Free Cash Flow to Firm to Interest Expense		 -9.32 -1.44 -5.74 -3.68 18.17 -67.87 -414.63 -621.60 -1,451.54 -1.42 -1,913.70
Operating Cash Flow to Interest Expense		 -15.44 -5.50 -15.06 -6.28 15.67 -25.50 -294.50 -112.00 -310.20 -0.77 -1,331.50
Operating Cash Flow Less CapEx to Interest Expense		 -15.68 -5.51 -15.06 -6.28 15.00 -25.60 -296.50 -112.38 -313.00 -0.77 -1,338.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.06 0.06 0.08 0.11 0.09 0.04 0.02 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 62.87 64.17 29.45 155.15 75.82 52.45 9.19 3.05 4.30 5.67 11.79
Inventory Turnover		 33.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.16 1.57 2.28 3.96 3.10 2.33 1.43 0.20 0.62 0.88 1.29
Accounts Payable Turnover		 2.86 4.97 5.68 4.87 3.96 3.38 1.86 0.45 0.33 0.41 0.50
Days Sales Outstanding (DSO)		 5.81 5.69 12.39 2.35 4.81 6.96 39.72 119.57 84.82 64.41 30.96
Days Inventory Outstanding (DIO)		 11.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 127.64 73.42 64.26 74.98 92.12 108.03 196.06 813.69 1,117.60 884.37 731.52
Cash Conversion Cycle (CCC)		 -110.77 -67.73 -51.87 -72.63 -87.30 -101.07 -156.34 -694.12 -1,032.78 -819.96 -700.56
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.54 -0.57 -0.14 -3.61 -4.76 -1.81 -1.78 -2.03 -2.26 -2.57 -2.87
Invested Capital Turnover		 0.91 1.15 1.58 -9.39 -1.42 -1.67 -1.06 -0.01 -0.02 -0.04 -0.05
Increase / (Decrease) in Invested Capital		 -4.30 -6.40 -5.14 -6.37 -5.30 -1.24 -1.64 1.58 2.50 -0.76 -1.09
Enterprise Value (EV)		 96 91 85 17 8.00 -8.41 -4.17 -1.03 -5.00 26 9.13
Market Capitalization		 38 20 7.69 13 6.95 12 11 9.45 6.55 65 43
Book Value per Share		 ($0.47) ($7.83) ($8.17) ($0.78) ($0.53) $1.11 $0.74 $0.39 $0.31 $5.60 $4.29
Tangible Book Value per Share		 ($0.48) ($7.95) ($8.27) ($0.78) ($0.53) $1.11 $0.74 $0.39 $0.31 $5.60 $4.29
Total Capital		 20 25 25 23 22 48 38 33 33 40 34
Total Debt		 44 46 44 32 29 6.60 6.80 6.90 11 15 15
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15 15
Net Debt		 25 20 19 5.77 2.28 -43 -33 -28 -25 -28 -22
Capital Expenditures (CapEx)		 0.18 0.04 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.02 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.12 -5.44 -4.68 -4.14 -5.37 -2.24 -2.22 -2.47 -2.72 -2.71 -3.01
Debt-free Net Working Capital (DFNWC)		 15 20 21 -3.38 -4.18 0.46 1.78 0.63 -1.18 3.75 0.77
Net Working Capital (NWC)		 -30 -25 -23 -35 -33 -6.14 -5.02 -6.27 -12 3.75 0.77
Net Nonoperating Expense (NNE)		 5.94 8.69 5.34 -72 -6.33 -24 9.02 2.62 -2.00 -4.56 1.68
Net Nonoperating Obligations (NNO)		 25 20 19 5.77 2.28 -43 -33 -28 -25 -28 -22
Total Depreciation and Amortization (D&A)		 0.73 0.59 0.31 0.24 0.07 0.04 0.02 0.02 0.02 0.02 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 -208.73% -180.27% -122.28% -102.68% -179.20% -112.54% -217.84% -8,520.69% -3,828.17% -3,188.24% -2,691.07%
Debt-free Net Working Capital to Revenue		 592.21% 666.41% 543.67% -83.71% -139.63% 22.93% 174.71% 2,179.31% -1,661.97% 4,411.76% 687.50%
Net Working Capital to Revenue		 -1,210.40% -843.53% -605.46% -878.21% -1,111.25% -308.23% -491.96% -21,613.79% -17,295.77% 4,411.76% 687.50%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.90) ($2.62) $0.00 $6.43 $125.10 $38.40 ($22.20) ($0.29) ($81.90) ($4.42) ($0.87)
Adjusted Weighted Average Basic Shares Outstanding		 8.37M 8.69M 9.15M 10.01M 10.75K 462.54K 602.82K 21.55M 22.35K 1.58M 6.27M
Adjusted Diluted Earnings per Share		 ($1.90) ($2.62) ($1.19) $1.44 $125.10 $10.20 ($22.20) ($0.29) ($81.90) ($4.42) ($0.87)
Adjusted Weighted Average Diluted Shares Outstanding		 8.37M 8.69M 9.15M 44.48M 72.45K 1.75M 602.82K 21.55M 22.35K 1.58M 6.27M
Adjusted Basic & Diluted Earnings per Share		 ($1.90) $0.00 $0.00 $0.00 $125.10 $0.00 $0.00 $0.00 ($81.90) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 10.62M 9.43M 10.41M 11.07M 559.57K 587.27K 731.10K 29.67M 212.77K 7.27M 8.00M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -9.83 -9.58 -8.10 -3.63 -3.81 -3.30 -3.39 -4.76 -5.62 -4.92
Normalized NOPAT Margin		 -1,093.17% -972.79% -978.43% -813.71% -36,323.00% -47,652.50% -55,008.33% -67,816.00% -9,155.19% -25,565.91% -14,895.15%
Pre Tax Income Margin		 -1,659.39% -1,832.87% -1,523.39% 6,095.48% 11,420.00% 232,787.50% -205,400.00% -120,220.00% -5,301.92% -4,836.36% -19,993.94%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -21.76 -6.79 -18.41 -7.23 191.00 301.24 -3,082.00 -751.63 -551.00 0.68 -3,303.00
NOPAT to Interest Expense		 -14.91 -4.12 -12.38 -8.18 -864.83 -87.84 -825.13 -423.85 -952.14 -1.64 -2,457.70
EBIT Less CapEx to Interest Expense		 -22.00 -6.81 -18.41 -7.23 190.33 301.15 -3,084.00 -752.00 -553.80 0.68 -3,309.50
NOPAT Less CapEx to Interest Expense		 -15.15 -4.14 -12.38 -8.19 -865.50 -87.94 -827.13 -424.23 -954.94 -1.65 -2,464.20
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.17% 0.16% 0.00% -4.41% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

PAVmed’s latest statements show modest revenue growth but continued heavy operating losses and cash consumption. Revenue increased to $33,000 in Q2 2026 from $22,000 in Q1 2026 and $6,000 in the restated Q2 2025. However, revenue remains extremely small relative to the company’s cost structure. Gross losses persisted, totaling $89,000 in Q2, while operating expenses reached $6.93 million.

  • Revenue improved sequentially: Q2 2026 revenue rose approximately 50% from Q1 2026, although the absolute level remains immaterial compared with operating expenses.
  • Operating expenses declined quarter over quarter: Total operating expenses fell from $7.96 million in Q1 2026 to $6.93 million in Q2. SG&A declined by roughly $1.7 million, partially offset by higher research and development spending.
  • Debt structure improved from prior periods: Short-term debt was reported at zero in Q1 and Q2 2026, compared with $6.9 million in Q3 2025 and more than $40 million in short-term debt during portions of 2023 and 2024.
  • Long-term investments remain a significant asset: PAVmed reported $33.5 million of long-term investments at June 30, 2026, representing the majority of its $40.2 million in total assets.
  • Q2’s net loss was driven primarily by operations: The company reported a $7.02 million operating loss, partially offset by $424,000 of net other income. This compares with a $1.06 million net loss in Q1, which benefited from a much larger $6.97 million other-income contribution.
  • Historical earnings have been volatile: PAVmed reported a $60.7 million net income in Q3 2024, largely reflecting $72.4 million of interest and investment income, but subsequently recorded losses of $2.76 million in Q4 2024, $12.32 million in Q2 2025, and $6.60 million in Q2 2026. The historical gains do not appear representative of recurring operating performance.
  • Capital structure data is difficult to compare: Reported weighted-average basic shares changed from 670,466 in Q4 2025 to 1.58 million in Q1 2026 and 6.27 million in Q2 2026. Reverse splits, recapitalizations or other capital-structure changes may affect these comparisons, but the figures highlight substantial equity-related complexity.
  • Cash flow remains deeply negative: Net cash used in operating activities was $2.66 million in Q2 2026, compared with $2.62 million in Q1 and $1.18 million in the restated Q2 2025. The company also used $2.68 million of cash during Q2 after capital expenditures.
  • Liquidity has deteriorated during 2026: Cash and equivalents fell from $6.46 million at March 31, 2026, to $3.78 million at June 30, despite a $4.92 million increase in cash during Q1. At the Q2 operating burn rate, reported cash alone would cover roughly one to two quarters without additional financing or asset sales.
  • Losses remain substantial relative to revenue: PAVmed’s $6.60 million consolidated Q2 net loss and $5.48 million loss attributable to common shareholders were generated on only $33,000 of revenue. Basic and diluted loss per share was reported at $0.87, underscoring the company’s continued dependence on outside capital and non-operating sources of income.

Investor takeaway: The balance sheet is stronger than it was during the severe liquidity pressure visible in 2023 and early 2024, with no reported short-term debt and meaningful long-term investments. Nevertheless, PAVmed has not demonstrated a sustainable operating business: revenue remains negligible, gross margins are negative, operating losses continue, and cash declined sharply in the latest quarter. Investors should closely monitor cash levels, financing activity, investment monetizations, debt obligations and any additional equity issuance.

08/22/26 11:30 PM ETAI Generated. May Contain Errors.

PAVmed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, PAVmed's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

PAVmed's net income appears to be on an upward trend, with a most recent value of -$2.47 million in 2025, rising from -$1.78 million in 2015. The previous period was $28.43 million in 2024. Check out PAVmed's forecast to explore projected trends and price targets.

PAVmed's total operating income in 2025 was -$21.81 million, based on the following breakdown:
  • Total Gross Profit: -$147 thousand
  • Total Operating Expenses: $21.66 million

Over the last 10 years, PAVmed's total revenue changed from $0.00 in 2015 to $71 thousand in 2025, a change of 7,100,000.0%.

PAVmed's total liabilities were at $16.51 million at the end of 2025, a 56.2% decrease from 2024, and a 2,746.1% increase since 2015.

In the past 10 years, PAVmed's cash and equivalents has ranged from $585.68 thousand in 2016 to $77.26 million in 2021, and is currently $1.54 million as of their latest financial filing in 2025.

Over the last 10 years, PAVmed's book value per share changed from 0.06 in 2015 to 0.31 in 2025, a change of 457.1%.


Related Companies

Financial statements for NASDAQ:PAVM last updated on 8/21/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Pass by August 7… or wait until 2027?
Crypto is moving again in a big, big way… But I'm most interested in an altcoin very few investors have on the...
Crypto 101 Media | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel